Search - tctmd.com

Displaying 101 - 120 of 177

Sort: Relevancy | Date

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

News Daily News

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

L.A. McKeown

April 17, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Conference News EHRA 2019

High-Dose Nifedipine Tied to Higher Cardiac Arrest Risk

Todd Neale

March 18, 2019

News Conference News

Flu Vaccination Tied to Less MI in Hospitalized Patients

Todd Neale

March 13, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Daily News

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Michael O'Riordan

November 23, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Michael O'Riordan

October 15, 2018

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Shelley Wood

August 28, 2018

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Shelley Wood

August 26, 2018

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

News Daily News

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Michael O'Riordan

August 13, 2018

News Conference News EuroPCR 2018

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

Shelley Wood

May 22, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

News Daily News

Varenicline Boosts Long-term Quit Rate in Post-ACS Smokers: EVITA

Caitlin E. Cox

March 26, 2018

Advertisement

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

High-Dose Nifedipine Tied to Higher Cardiac Arrest Risk

Flu Vaccination Tied to Less MI in Hospitalized Patients

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Varenicline Boosts Long-term Quit Rate in Post-ACS Smokers: EVITA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content